SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 5 of 85
Word Count: 1440
Character Count: 9473

Document Content:

trials may be delayed, suspended or terminated for many reasons, which will increase our expenses and delay the time it takes to develop new product candidates or seek new indications. depend on a limited number of manufacturers and suppliers in connection with the manufacture of the Revivent System, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition, results of operations, and prospects. ● The report of our independent registered public accounting firm for the year ended December 31, 2025 includes a “going concern” explanatory paragraph. are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success. ● Product liability claims could damage our reputation and adversely affect our financial results. Risks Related to Our Intellectual Property and Technology

we experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary
or confidential data, employee data or personal data, or if customers, patients and other partners are reluctant to use our devices
because of concerns about the privacy or security of their data, we may face additional costs, loss of revenue, significant liabilities,
harm to our brand, decreased use of our platform and business disruption.

will be required to comply with our obligations in our intellectual property licenses and other agreements with third parties.

we are unable to adequately protect our proprietary technology or obtain and maintain issued patents that are sufficient to protect
our product candidates, product candidates, and methods others could compete against us more directly, which could harm our business,
financial condition and results of operations.

may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights
and we may be unable to protect our rights to, or use of, our technology.

●	Intellectual
property rights do not necessarily address all potential threats.

Risks
Related to Regulatory Approval and Other Governmental Regulations

intend to expand sales of any approved product candidates internationally in the future, but we may experience difficulties in obtaining
regulatory clearance or approval in the United States or in successfully marketing our product candidates internationally even if
approved. A variety of risks associated with marketing our product candidates internationally could materially adversely affect our
business.

we fail to obtain and maintain necessary governmental approvals for our product candidates and indications, we may be unable to market
and sell our product candidates in certain jurisdictions.

●	Our
product candidates are subject to extensive regulatory requirements, including continuing regulatory review, which could affect the
manufacturing and marketing of our product candidates.

●	Our
product candidates may be subject to extensive governmental regulation in foreign jurisdictions, such as the European Economic Area
(EEA), and our failure to comply with applicable requirements could cause our business, results of operations and financial condition
to suffer.

●	The
FDA regulatory approval, clearance and license process is complex, time-consuming and unpredictable.

●	While
BDD allows for increased interaction with FDA reviewers and prioritized submission review, it does not guarantee product approval,
faster approval, or commercial success.

Risks
Related to Our Securities and this Offering

●	The
trading price of our common stock may be volatile, and you could lose all or part of your investment.

●	Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.

●	Our
management will have broad discretion in how we use the net proceeds from this offering and might not use them effectively.

●	You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

Implications
of Being an Emerging Growth Company

qualify as an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).
For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies. These provisions include, but are not limited to:

●	being
permitted to have only two years of audited financial statements and only two years of related management’s discussion and
analysis of financial condition and results of operations disclosure;

exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”);

●	reduced
disclosure about executive compensation arrangements in our periodic reports, registration statements, and proxy statements; and

●	exemptions
from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.

particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive
compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained
herein may be different from the information you receive from other public companies in which you hold stock.

addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies. We are not choosing to “opt out” of this provision. We will remain an
emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.235
billion, (ii) the date on which we first qualify as a large accelerated filer under the rules of the Securities and Exchange Commission
(the “SEC”), (iii) the date on which we have, in any three-year period, issued more than $1.0 billion in non-convertible
debt securities, and (iv) the last day of the fiscal year following the fifth anniversary of the completion of this offering.

Implications
of Being a Smaller Reporting Company

Following
this offering, we will be a “smaller
reporting company” as defined in Rule 12b-2 under the Exchange Act. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock
held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues
are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates
is less than $700 million measured on the last business day of our second fiscal quarter.

Corporate
Information

We are currently
a Delaware corporation. Our predecessor, CHF Technologies,
Inc., was incorporated under the laws of the State of California on October 15, 2003. On June 8, 2012, we incorporated BioVentrix, Inc.
under the laws of the State of Delaware, which subsequently merged into CHF Technologies, Inc., with BioVentrix, Inc. as the surviving
corporation in the merger. Our principal executive office is located at 120 Forbes Blvd., Suite 125, Mansfield, MA 02048. Our telephone
number is (925) 290-1000 and our website is www.bioventrix.com. Information contained on, or available through, our website
does not constitute part of, and is not deemed incorporated by reference into, this prospectus, and investors should not consider any
such information as part of this prospectus.

THE
OFFERING

Common
Stock Offered by Us shares
of common stock on a firm commitment basis (or shares of common stock if the underwriters exercise their over-allotment option in
full).

Common
Stock Outstanding Prior to This Offering 5,712,645
shares of common stock outstanding as of December 31, 2025.

Common
Stock to Be Outstanding Immediately After Completion of This Offering (1) shares
of common stock (or            shares of common stock if the underwriters
exercise their over-allotment option in full).

Over-allotment
Option We
have granted the underwriters a 30-day option to purchase up to an additional
shares of our common stock at the initial public offering price, less underwriting discounts and commissions, solely to cover over-allotments,
if any.

Use
of Proceeds We
estimate that the net proceeds to us from this offering, after deducting the underwriting
discounts and estimated offering expenses payable by us, will be approximately $
million, or approximately $          million
if the underwriters exercise their over-allotment option in full, based on the assumed initial
public offering price of $         per share.

The
net proceeds received by us from this offering will be used primarily to fund the RELIVE clinical trial and the associated manufacturing
activities required to support such trial. The remaining portion of the net proceeds will be used to fund working capital and general
and administrative expenses. See “ Use of Proceeds .”